View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 15, 2021updated 11 Jul 2022 2:48pm

CalciMedica’s drug lowers mortality rate in Phase II Covid-19 trial

Auxora was found to be well-tolerated, with a smaller proportion of subjects in the Auxora arm experiencing serious adverse events.

CalciMedica has reported top-line results from the Phase II CARDEA clinical trial of its lead drug candidate, Auxora, in severe Covid-19 pneumonia patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Auxora is an intravenous (IV) formulated small molecule that selectively inhibits the calcium release-activated calcium (CRAC) channel.

The drug hinders acute epithelial and endothelial cell injury and inflammation in organs, including the pancreas and lungs.

The randomised, double-blind, placebo-controlled Phase II trial enrolled 284 Covid-19 pneumonia patients who were in the hospital and receiving supplemental oxygen through a high flow nasal cannula or low flow device.

Initially, the company planned to enrol up to 400 subjects, but the enrolment was halted owing to the reduced number of Covid-19 cases and hospitalisations.

CalciMedica also attributed the halt to modifications in the standard of care (SOC) that comprised immunosuppressive therapies not included in the trial protocol.

The trial randomised 281 subjects in a 1:1 ratio to receive a minimum of one dose of either Auxora plus SOC or placebo plus SOC.

It had 261 subjects with moderate or severe respiratory failure and 23 participants with mild respiratory failure.

All subjects received SOC treatment with corticosteroids and more than 99% also received prophylactic anticoagulation treatment.

The time to recovery through day 60 was the trial’s primary goal.

In the 261-subject efficacy dataset, the median time to recovery was seven days for subjects in the Auxora arm versus ten days in the placebo arm, indicating a recovery ratio of 1.25.

In the 281-subject safety dataset, the median time to recovery was seven days for subjects receiving Auxora as against eight days in the placebo arm, signifying a recovery ratio of 1.30.

On the key secondary goal of all-cause mortality by day 60 and a supportive secondary goal of all-cause mortality by day 30 assessed in the 261-subject efficacy dataset, Auxora attained statistical significance.

In the Auxora arm, the 30-day all-cause mortality was 7.7% versus 17.6% for placebo, showing a 56% relative risk reduction and 9.9% absolute risk reduction for mortality.

The 60-day all-cause mortality was 13.8% in the Auxora group as against 20.6% in the placebo arm, indicating a 33% and 6.8% relative mortality risk reduction and absolute mortality risk reduction, respectively.

Findings also showed that Auxora was well-tolerated with a reduced proportion of 24.1% of subjects in the drug arm experiencing serious adverse events (SAEs) versus 35% in the placebo arm.

CalciMedica chief medical officer Sudarshan Hebbar said: “Initial efficacy signals for both time to recovery and mortality in CARDEA suggest that Auxora may rapidly reduce inflammation and reduce damage to vital organ tissue—both key in the fight against disease progression.

“These signals were observed even though we did not power the study for mortality endpoints, and we decided to halt enrolment before reaching our target.”

The company plans to discuss the trial results with the US Food and Drug Administration (FDA) and to assess additional opportunities to evaluate Auxora in Covid-19 patients.

In February, CalciMedica reported positive clinical data from the trial of Auxora in patients with severe Covid-19 pneumonia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena